• Ali Akbar Taheraghdam, Ehsan Sharifipour, Ali Pashapour, Shahryar Namdar, Abolfazl Hatami, Samaneh Houshmandzad, Elyar Sadeghihokmabadi, Mokhtar Tazik, Reza Rikhtegar, and Ata Mahmoodpoor.
• Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
• Med Princ Pract. 2014 Jan 1; 23 (2): 134-9.

ObjectivesTo assess the clinical relevance (functional outcome) of a 3-month allopurinol regimen in patients with high serum uric acid (SUA) levels and acute ischemic stroke without considering the changes in SUA levels.Materials And MethodsIn a randomized, double-blind, controlled study, 70 patients (45 females, 25 males) with acute ischemic stroke who had elevated levels of SUA were included. They were divided in two 35-patient groups to investigate the effect of 3 months of an allopurinol (200 mg/day) regimen versus placebo on their functional outcome, which was evaluated using a modified Rankin scale.ResultsThe overall mean age was 68.9 ± 11.33 years (range 27-89). The final favorable functional status (mRS = 0-2) was 23 (65.7%) and 14 (40.0%) in the treated and placebo groups, respectively, which was strongly associated with allopurinol consumption (OR = 4.646, p = 0.014) and age ≤70 years (OR = 0.139, p = 0.005) in patients with ischemic stroke after adjusting for confounders. There was no significant difference in death between allopurinol-treated cases (3; 8.6%) and placebo-treated ones (6; 17.2%; p = 0.278).ConclusionAllopurinol treatment was well tolerated and improved the 3-month functional status of patients with acute ischemic stroke who had high levels of SUA without considering the decreasing effect of allopurinol on SUA.© 2013 S. Karger AG, Basel.

22 keywords...

hide…